All In Biotech

Drug Trial Radar · NCT04215978

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

204

Actual

Start

Jan 30, 2020

Primary completion

Jan 24, 2025

Study completion Jan 24, 2025

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jan 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.

Conditions

  • Advanced Solid Tumor
  • Non Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Nasopharyngeal Carcinoma (NPC)

Interventions

  • BGB-A445Drug

    Administered as specified in the treatment arm

  • tislelizumabDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
  2. Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
  3. Phase 1a: Number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteriaTime frame: Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
  4. Phase 1a: Maximum Tolerated Dose (MTD) of BGB-A445Time frame: Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
  5. Phase 1b: RP2D of BGB-A445 when Administered AloneTime frame: Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
  6. Phase 1b: Overall Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first

Locations

30 sites in 8 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California

  • California Cancer Associates for Research & Excellence (cCARE)

    San Diego, California

  • UPMC Hillman Cancer Center (Univ Of Pittsburgh)

    Pittsburgh, Pennsylvania

  • Blacktown Cancer And Haematology Centre

    Blacktown, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Nucleus Network

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology

    Wuhan, Hubei, China

  • The Second Xiangya Hospital Of Central South University

    Changsha, Hunan, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Affiliated Zhongshan Hospital Of Fudan University

    Shanghai, Shanghai Municipality, China

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • University of Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Sarawak General Hospital

    Kuching, Malaysia

  • Auckland City Hospital

    Auckland, New Zealand

  • National Cancer Center (NCC)

    Goyang-si, Gyeonggi-do, South Korea

  • Cha Bundang Medical Center, Cha University

    Gyeonggido, Gyeonggi-do, South Korea

  • The Catholic University of Korea, St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggido, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, Seoul Teugbyeolsi, South Korea

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Changhua Christian Hospital

    Changhua, NAP, Taiwan

  • King Chulalongkorn Memorial Hospital (Chulalongkorn University)

    Bangkok, Thailand

  • Ramathibodi Hospital Mahidol University

    Bangkok, Thailand

  • Srinagarind Hospital (Khon Kaen University)

    Muang, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.